The introduction of
nanocarriers as delivery vehicles for common chemotherapy agents such as the drug irinotecan, has led to improved survival of patients with this disease.
Not exact matches
A common assumption is that once a
nanocarrier is created, it maintains its size and shape on the shelf
as well
as in the body.
Nanocarriers can also deliver drugs and diagnostic agents that are typically not soluble in water or blood
as well
as significantly decrease the effective dosage.
Berkeley Lab researchers have developed a new family of
nanocarriers, called «3HM,» that meets all the size and stability requirements for effectively delivering therapeutic drugs to the brain for the treatment of a deadly form of cancer known
as glioblastoma multiforme.
Nanotechnology has the potential to satisfy these requirements if some of its intrinsic shortcomings can be solved: rapid uptake of
nanocarriers by RES and the toxicity
as a result, and drug release outside the tumor, especially the early burst release when the fast drug release is coupled with high blood... more»
«These
nanocarriers developed by our team have a variety of applications in medication and
as a gene transfection agent for biological research,» said Dr Yi - Yan Yang, who led the project team comprising Yong Wang, Shujun Gao, Wen - Hui Ye and Ho Sup Yoon.